Belgium-based molecular diagnostics provider MDxHealth has entered a scientific agreement with Australia-based Queensland University of Technology’s (QUT) commercialisation unit, QUT bluebox, to develop a new liquid biopsy epigenetic test for early detection of oral cancer.

Under the terms of the agreement, MDxHealth and QUT will jointly evaluate and develop the test, while the former will hold the first option to licence the commercial diagnostics rights.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

MDxHealth intends to use the proceeds from the commercialisation to support its R&D diagnostics for urologic cancer, as well as additional research and translational activities at QUT and the Institute of Health and Biomedical Innovation (IHBI).

MDxHealth CEO Dr Jan Groen said: "A simple and fast point of care test could help dentists to rule out oral cancer while you have your dental check-up.

"A simple and fast point of care test could help dentists to rule out oral cancer while you have your dental check-up."

"This scientific collaboration is an opportunity for both MDxHealth and QUT to leverage existing know-how to develop a ground-breaking oral cancer test that will improve overall survival for thousands of patients."

The epigenetic assay is designed to assess abnormal DNA methylation changes that are believed to be an early occurrence during the progression of the tumour.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

QUT School of Biomedical Sciences and Institute of Health and IHBI associate professor Dr Chamindie Punyadeera said: "Our test is expected to facilitate much earlier detection of oral cancer and potentially precancerous lesions by a variety of specialties, including general practitioners, oncologists and dentists.”

Dr Punyadeera, who is also the project’s lead investigator, added that the collected saliva swab samples will be sent to a lab or tested onsite to determine the need for a clinical follow-up.